MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.
Visani G, Loscocco F, Ruzzo A, Galimberti S, Graziano F, Voso MT, Giacomini E, Finelli C, Ciabatti E, Fabiani E, Barulli S, Volpe A, Magro D, Piccaluga P, Fuligni F, Vignetti M, Fazi P, Piciocchi A, Gabucci E, Rocchi M, Magnani M, Isidori A.
Visani G, et al.
Pharmacogenomics J. 2018 May 22;18(3):444-449. doi: 10.1038/tpj.2017.48. Epub 2017 Dec 5.
Pharmacogenomics J. 2018.
PMID: 29205204